These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33898117)

  • 1. Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator.
    Verma D; Hussain K; Namiq KS; Firoz A; Bouchama M; Raza M; Haris M; Khan S
    Cureus; 2021 Mar; 13(3):e14029. PubMed ID: 33898117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.
    Agarwal P; Rashighi M; Essien KI; Richmond JM; Randall L; Pazoki-Toroudi H; Hunter CA; Harris JE
    J Invest Dermatol; 2015 Apr; 135(4):1080-1088. PubMed ID: 25521459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitiligo and Autoimmune Thyroid Disorders.
    Baldini E; Odorisio T; Sorrenti S; Catania A; Tartaglia F; Carbotta G; Pironi D; Rendina R; D'Armiento E; Persechino S; Ulisse S
    Front Endocrinol (Lausanne); 2017; 8():290. PubMed ID: 29163360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond skin white spots: Vitiligo and associated comorbidities.
    Hu Z; Wang T
    Front Med (Lausanne); 2023; 10():1072837. PubMed ID: 36910477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo.
    Zhang S; Zdravković TP; Wang T; Liu Y; Jin H
    J Investig Med; 2021 Feb; 69(2):393-396. PubMed ID: 33093072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of
    Mahdian D; Abbaszadeh-Goudarzi K; Raoofi A; Dadashizadeh G; Abroudi M; Zarepour E; Hosseinzadeh H
    Iran J Basic Med Sci; 2020 Nov; 23(11):1374-1381. PubMed ID: 33235693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etiological Association Between Psoriasis and Thyroid Diseases.
    Eapi S; Chowdhury R; Lawal OS; Mathur N; Malik BH
    Cureus; 2021 Jan; 13(1):e12653. PubMed ID: 33585138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo.
    Laberge G; Mailloux CM; Gowan K; Holland P; Bennett DC; Fain PR; Spritz RA
    Pigment Cell Res; 2005 Aug; 18(4):300-5. PubMed ID: 16029422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4.
    Amerio P; Tracanna M; De Remigis P; Betterle C; Vianale L; Marra ME; Di Rollo D; Capizzi R; Feliciani C; Tulli A
    Clin Exp Dermatol; 2006 Sep; 31(5):746-9. PubMed ID: 16803462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and Safety Evaluation of Topical Simvastatin Loaded NLCs for Vitiligo.
    Yazdani Ashtiani S; Ahmad Nasrollahi S; Naeimifar A; Nassiri Kashani A; Samadi A; Yadangi S; Aboutaleb E; Abdolmaleki P; Dinarvand R; Firooz A
    Adv Pharm Bull; 2021 Jan; 11(1):104-110. PubMed ID: 33747857
    [No Abstract]   [Full Text] [Related]  

  • 11. Comorbidities in vitiligo: comprehensive review.
    Dahir AM; Thomsen SF
    Int J Dermatol; 2018 Oct; 57(10):1157-1164. PubMed ID: 29808541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of vitamin D in melanogenesis with an emphasis on vitiligo.
    AlGhamdi K; Kumar A; Moussa N
    Indian J Dermatol Venereol Leprol; 2013; 79(6):750-8. PubMed ID: 24177606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into immune mechanisms of vitiligo.
    Boniface K; Taïeb A; Seneschal J
    G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
    Niezgoda A; Winnicki A; Kosmalski T; Kowaliszyn B; Krysiński J; Czajkowski R
    Trials; 2019 Jan; 20(1):78. PubMed ID: 30683146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To Assess Metabolic Syndrome in Patients of Vitiligo Attending a Tertiary Care Hospital in Central India.
    Gourh V; Dubey A
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vitiligo in multiple autoimmune syndrome: a retrospective study of 11 cases and a review of the literature].
    Klisnick A; Schmidt J; Dupond JL; Bouchou K; Rousset H; Thieblot P; Humbert P; Vidal E; Aumaître O
    Rev Med Interne; 1998 May; 19(5):348-52. PubMed ID: 9775171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prevalence of autoimmune endocrine diseases in vitiligo patients].
    Troshina EA; Volnukhin VA; Petrov VA; Nuralieva NF; Yukina MY; Orlova EM; Frigo NV
    Ter Arkh; 2020 Nov; 92(10):88-96. PubMed ID: 33346485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analysis of genetics and associated autoimmune diseases in Chinese vitiligo patients.
    Zhang Z; Xu SX; Zhang FY; Yin XY; Yang S; Xiao FL; Du WH; Wang JF; Lv YM; Tang HY; Zhang XJ
    Arch Dermatol Res; 2009 Feb; 301(2):167-73. PubMed ID: 18839195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro TyRP-1 Knockdown Based on siRNA Carried by Liquid Crystalline Nanodispersions: an Alternative Approach for Topical Treatment of Vitiligo.
    Tofani LB; Depieri LV; Campos PM; Riul TB; Antonietto KS; de Abreu Fantini MC; Bentley MVLB
    Pharm Res; 2018 Mar; 35(5):104. PubMed ID: 29560584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Risk of Metabolic Syndrome in Patients with Vitiligo.
    Ataş H; Gönül M
    Balkan Med J; 2017 May; 34(3):219-225. PubMed ID: 28443562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.